The FDA just approved the first mRNA flu shot, a year to the day after Washington cut off federal mRNA vaccine funding
On 5 August 2026 the FDA approved mFlusiva, Moderna's mRNA influenza vaccine and the first of its kind for seasonal flu. It arrived exactly one year after the government cancelled roughly $500 million in mRNA vaccine work, and only after the agency's own vaccine chief moved to block it, then reversed. Here is what the shot does, and the fight behind it.
On 5 August 2026 the US Food and Drug Administration approved mFlusiva, made by Moderna, the first mRNA-based vaccine for seasonal influenza. In a 40,805-person trial across 11 countries, Moderna reported it was about 27% (26.6%) better than a standard-dose flu shot at preventing lab-confirmed flu. It has full approval for adults 50 to 64 and accelerated approval for those 65 and older. The timing drew immediate attention: the approval fell one year to the day after the government cancelled roughly $500 million in federal mRNA vaccine work, and it came only after the FDA's own vaccine director first moved to block the application, before the agency reversed course just over two weeks later.
For a technology that spent 2025 being defunded in Washington, mRNA had a striking 2026. On 5 August the FDA approved Moderna's mFlusiva, the first messenger-RNA vaccine cleared for seasonal flu rather than Covid. It is a real scientific milestone, and it landed in the middle of a political fight that makes the milestone hard to separate from the story around it. Here is what was actually approved, how well it works, and why the date matters.
What did the FDA actually approve?
mFlusiva is a seasonal influenza vaccine that uses the same messenger-RNA approach as the Covid shots: instead of a grown or inactivated virus, it delivers genetic instructions that tell your cells to make a viral protein your immune system learns to recognise. The FDA gave it:
- Full (traditional) approval for adults aged 50 to 64.
- Accelerated approval for adults 65 and older, which comes with a requirement for Moderna to run a further confirmatory study in that older group.
The approval rests on a large late-stage trial: 40,805 adults across 11 countries. In it, Moderna's vaccine was reported to be about 27% (26.6%) more effective than a licensed standard-dose flu shot at preventing test-confirmed influenza. Moderna has said it expects to have doses available in time for the 2026-2027 flu season.
Two things are worth stating plainly, because vaccine news is easy to over-read. First, this is a shot for older adults, not a universal or childhood flu vaccine, and not a pandemic vaccine. Second, "first mRNA flu vaccine" is a genuine first for the influenza platform, but mRNA itself is not new: it has been in hundreds of millions of arms as a Covid vaccine since 2020.
Why did the approval date draw so much attention?
The approval date is the part everyone noticed. Exactly one year earlier, on 5 August 2025, the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. announced it was cancelling 22 mRNA vaccine development projects worth roughly $500 million, wound down through BARDA, the federal agency that funds defences against pandemics and biological threats. HHS said at the time it was acting on safety and effectiveness concerns it attributed to mRNA Covid and flu vaccines. The cuts hit contracts and proposals spanning companies and universities, and drew immediate criticism from researchers who argued they undercut pandemic preparedness.
So an mRNA flu vaccine winning approval one year to the day later was, unsurprisingly, read as a rebuke. STAT and other outlets framed mFlusiva's clearance as evidence that the platform Washington had just defunded was delivering results. That framing is a commentary, not an official finding, and it is worth keeping the two apart: the FDA approved a specific vaccine on its trial data; whether that vindicates or contradicts the 2025 funding decision is an argument, and we are flagging it as one.
Didn't the FDA try to block this first?
It nearly did. On 3 February 2026, the FDA's then vaccine director, Dr Vinay Prasad, issued a rare "refusal-to-file" notice on Moderna's application. His stated objection was methodological: the trial had compared mFlusiva against a standard-dose flu shot, rather than against the adjuvanted or high-dose vaccines of the kind specifically recommended for people 65 and older. In other words, he argued the study had not proven itself against the toughest relevant comparator for the oldest group.
That block did not hold. After a meeting with the company and a wave of public criticism, the FDA reversed the refusal on 18 February 2026, 15 days later, and accepted a revised application. Moderna restructured its request into the shape that was ultimately approved: full approval for the 50-to-64 group where its data were strongest, and accelerated approval for the 65-and-older group, paired with a commitment to further study. (Prasad left the FDA in April 2026; the agency did not link his departure to the mFlusiva decision.) In June, an FDA advisory committee of independent experts then reviewed the vaccine and voted unanimously to recommend it for both age groups.
How well does it work, and what are the side effects?
On effectiveness, the headline number is the trial's roughly 27% relative improvement over a standard-dose shot at preventing lab-confirmed flu. That is a meaningful edge, but read it precisely: it is a comparison against one class of existing vaccine in one trial, reported by the manufacturer, not a claim that the shot stops 27% of all flu.
On safety, the trial recorded more side effects in the mRNA group than in the standard-dose comparators. The common ones were the familiar post-vaccination reactions, injection-site pain, fatigue and headache, and they were mostly mild and lasted a day or two. The accelerated approval for the 65-and-older group is precisely why the FDA is requiring a confirmatory study: it leaned partly on additional immunogenicity data rather than on the headline efficacy result alone, and accelerated approval lets a product reach patients earlier on strong but not-yet-final evidence, with the follow-up data owed afterwards.
If you want the wider context on how fast biomedical tools are moving from lab to clinic this year, our piece on the blood test that can now help diagnose Alzheimer's is a useful companion, another 2026 FDA milestone with the same "genuine, but read the fine print" shape.
What this does and does not mean
The clean read is the fair one. A new class of flu vaccine cleared a large trial and a unanimous expert panel, and will be an option for older adults this season. It is also a platform, and platforms matter: the same mRNA approach that made this shot possible is the one being explored for other diseases, which is part of why the 2025 funding cuts were so contested. (For the biology of how genetic medicine is reshaping treatment more broadly, see our explainer on CRISPR gene editing in 2026.)
What it is not is a verdict in the political fight, or medical advice. Whether an individual should get this specific shot, versus a high-dose or standard flu vaccine, is a question for a clinician, not a headline. What the approval settles is narrower and still significant: the first mRNA flu vaccine exists, it cleared the bar, and it did so in the least quiet way imaginable.
Frequently asked questions
What is mFlusiva?
mFlusiva is Moderna's seasonal influenza vaccine and the first mRNA-based flu vaccine approved by the FDA, cleared on 5 August 2026. It uses the same messenger-RNA technology as the Covid vaccines, applied to flu.
Who can get it?
The FDA gave full approval for adults aged 50 to 64 and accelerated approval for adults 65 and older. It is aimed at older adults, not children, and Moderna expects doses to be available for the 2026-2027 flu season.
How effective is it?
In a 40,805-person trial across 11 countries, Moderna reported the vaccine was about 27% (26.6%) more effective than a standard-dose flu shot at preventing lab-confirmed influenza. That figure is a comparison against one existing vaccine class, reported by the manufacturer.
Why is the approval date significant?
It fell one year to the day after HHS, under Secretary Robert F. Kennedy Jr., announced on 5 August 2025 that it was cancelling 22 mRNA vaccine projects worth roughly $500 million. Commentators framed the approval as evidence for the platform that had just been defunded, though that is interpretation, not an official FDA position.
Did the FDA initially reject it?
The FDA's then vaccine director issued a refusal-to-file notice on 3 February 2026, arguing the trial should have used a high-dose comparator for the oldest group. The agency reversed that decision on 18 February 2026 after discussions with Moderna and public criticism, and an advisory panel later voted unanimously to recommend approval.
A blood test can now help diagnose Alzheimer's. Here's what that really means
Diagnosing Alzheimer's used to require an expensive brain scan or a spinal tap. In 2026 a simple blood test crossed from the research lab into the clinic, sharply improving how accurately doctors can identify the disease. It is a genuine turning point, and also not a crystal ball. Here is what these tests do, and what they do not.
For the first time, we can see whirlpools on the Sun's surface. They may explain why its atmosphere is so strangely hot
The world's largest solar telescope has taken the sharpest images ever of the Sun's surface and caught something long predicted but never seen there: tiny plasma whirlpools, only about 20 km across, the same wave-curl you get in ocean waves and clouds. They may be part of the answer to a decades-old mystery. Here is what was found, and what it does and does not prove.
JWST found a 'black hole star' in the early universe, and it might solve a real puzzle
The James Webb telescope spotted an object 660 million years after the Big Bang that looks like a giant star but is really a black hole wrapped in so much gas it disguises itself. If the interpretation holds, it helps explain one of astronomy's genuine mysteries: how monster black holes appeared so impossibly early. Here is the careful version.